Vaccine adjuvants: scientific challenges and strategic initiatives
- 1 March 2009
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 8 (3) , 293-298
- https://doi.org/10.1586/14760584.8.3.293
Abstract
(2009). Vaccine adjuvants: scientific challenges and strategic initiatives. Expert Review of Vaccines: Vol. 8, No. 3, pp. 293-298. doi: 10.1586/14760584.8.3.293Keywords
This publication has 22 references indexed in Scilit:
- Epaxal®: a virosomal vaccine to prevent hepatitis A infectionExpert Review of Vaccines, 2008
- Pathogen recognition by innate receptorsJournal of Infection and Chemotherapy, 2008
- Prepandemic Influenza Vaccine H5N1 (Split Virion, Inactivated, Adjuvanted) [Prepandrix™]BioDrugs, 2008
- GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectivesExpert Review of Vaccines, 2007
- MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infectionExpert Review of Vaccines, 2007
- Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiationExpert Review of Vaccines, 2007
- The Vaccine Adjuvant Monophosphoryl Lipid A as a TRIF-Biased Agonist of TLR4Science, 2007
- Toll or Toll-Free Adjuvant Path Toward the Optimal Vaccine DevelopmentJournal of Clinical Immunology, 2007
- Aluminium compounds for use in vaccinesImmunology & Cell Biology, 2004
- Aluminium adjuvants—in retrospect and prospectVaccine, 2004